Extraosseous accumulation of bone-seeking agents is rare, but has been previously reported in pediatric sarcomas and neuroblastomas. We present an unusual case of a 5-month-old male with an abdominal mass observed clinically by his parents and referring pediatrician. Contrast abdominal computerized tomography confirmed the presence of a large pelvic mass that was diagnosed pathologically as embryonal rhabdomyosarcoma. A bone scintigraphy that was performed for staging of the disease revealed accumulation of the radiopharmaceutical in the tumor. There was no evidence for skeletal metastatic disease. This case further demonstrates the nonspecificity of soft-tissue tumor uptake on bone scintigraphy.
CASE REPORT
A 5-month-old male was admitted to our institution with an abdominal mass that was observed clinically by his parents and referring pediatrician. The abdominal computerized tomography confirmed the presence of a large pelvic mass (figures 1, 2) that was diagnosed as embryonal rhabdomyosarcoma. The mass did not demonstrate calcifications on CT. A bone scintigraphy, performed for staging of the disease, revealed accumulation of the radiopharmaceutical in the tumor. No metastatic lesions were noted. (figure 3). The patient had chemotherapy and surgical resection of the tumor and is currently on remission.
Rhabdomyosarcoma is a malignant tumor that represents 5% of all childhood cancers [1] . In adults, rhabdomyosarcoma is rare, accounting for only 3% of the soft-tissue sarcomas [2] . The incidence of rhabdomyosarcoma is 6 cases per 1,000,000 per year in children and adolescents younger than 15 years.
Rhabdomyosarcoma is known to be more common in boys and in white children [3] .
In younger children rhabdomyosarcoma most often arises from the genitourinary tract, particularly from the bladder, prostate, and paratesticular, uterus and vagina [3] . In older children the tumor arises mainly from the neck, orbits, and extremities. In sonogram the tumor has heterogeneous variable nonspecific echotexture. The solid component of the lesion has been described as hyperechoic or hypoechoic and may contain sonolucent foci [4] . In CT the mass has usually heterogeneous appearance and enhances heterogeneously. Low attenuation usually represents necrosis. On MRI the mass has low signal on T1-weighted sequence and high signal on T2-weighted sequence. The mass usually heterogeneously enhances. A bone scintigraphy is usually performed during staging to screen for metastatic lesions. It is unlikely that boneseeking radiopharmaceutical will concentrate in the tumor.
The current classification for rhabdomyosarcoma includes embryonal (with the less common subtype botryoid and variant spindle cell) which have an intermediate to superior prognosis, DISCUSSION CASE REPORT alveolar (with a poorer prognosis), undifferentiated sarcoma (also with a poorer prognosis), and sarcoma not otherwise specified [4] . Although rhabdomyosarcoma shares certain imaging characteristics with other soft-tissue sarcomas, it has been reported that there are rather unique features at presentation which should make the radiologist consider the diagnosis. In a previous study, it was shown that tumor heterogeneity is more prominent in alveolar and pleomorphic subtypes of adult rhabdomyosarcoma. These subtypes were also noted to have extremely high signal on T2 and STIR MRI [5] . Contrary to adult rhabdomyosarcoma where alveolar rhabdomyosarcoma demonstrated more heterogeneity in cross sectional imaging, rhabdomyosarcoma in the pediatric population demonstrates no significant difference in attenuation between the alveolar and embryonal subtypes [6] .
Diagnosis of rhabdomyosarcoma depends on recognition of differentiation toward skeletal muscle cells. The proteins myoD1 and myogenin are transcription factor proteins normally found in developing skeletal muscle cells which disappears after the muscle matures and becomes innervated by a nerve. Thus, myoD1 and myogenin are not usually found in normal skeletal muscle and serve as a useful immunohistochemical marker of rhabdomyosarcoma [7] .
The differential diagnosis depends on the location of the tumor. The differential diagnosis for abdominal or pelvic rhabdomyosarcoma may include teratoma, neuroblastoma, Wilms tumor, lymphangioma, and lymphoproliferative disorders. The differential diagnosis of rhabdomyosarcoma that originated from the extremities although may be the same, but tumors that are more common in the extremities such as osteosarcoma, Ewing's sarcoma or synovial sarcoma need to be included. The imaging findings of most tumors that are included in the differential diagnosis list include heterogeneous variable nonspecific sonographic echotexture. Lymphoproliferative disorder demonstrates on sonography conglomerate of lymph nodes. Lymphangioma is seen on sonography as an anechoic cystic septated mass. Most of the solid tumors that are included in the differential diagnosis list demonstrate heterogeneous low attenuation on CT with variable enhancement. On MRI these tumors demonstrate low T1-weighted signal and high T2-weighted signal. Most of the tumors that are included in the differential diagnosis list do not demonstrate accumulation of bone-seeking radiopharmaceuticals, unless there are calcifications or bony elements in the tumor, such as in teratoma.
Treatment for rhabdomyosarcoma consists of chemotherapy, radiation therapy and sometimes surgery. Surgery to remove the tumor may depend on the location of the tumor.
Accumulation of bone-seeking agents in rhabdomyosarcoma is rare, but has been previously reported [8, 9, 10] . Accumulation of bone-seeking agents has also been observed in many benign and malignant tumors such as breast cancer [11] and liver tumors [12] . The mechanism of uptake of bone-seeking agents in rhabdomyosarcoma is not completely understood, but in our case it is suggested that phosphate compound binds to a damaged mitochondria in necrotic tumors [13] . Microcalcifications might have been produced due to ischemic changes and altered capillary permeability of the tumor. Dystrophic microcalcifications are not always detected in CT, but the link between these calcifications to ischemic and necrotic changes is well demonstrated [14] .
Uptake of bone-seeking radiopharmaceuticals by pediatric tumors is very nonspecific. It is seen in neuroblastomas and in neural-crest tumors [15] . Our case further illustrates the nonspecificity of soft-tissue tumor uptake in pediatric patients to include rhabdomyosarcoma.
Concentration of bone-seeking radiopharmaceuticals in soft tissue tumors is nonspecific and a rare event. It was described in neuroblastomas and in neural-crest tumors. We observed this unusual concentration of Tc-99m methylendiphosphonate in rhabdomyosarcoma. This may be explained by dystrophic calcifications that were produced in a necrotic tumor that are not always seen in CT. Nuclear radiologists should be aware of this rare event. 
FIGURES

Etiology
Unclear Incidence 5% of childhood cancers. 6 cases per 1,000,000 per year.
Gender ratio
More common in boys.
Age predilection
Children and adolescents younger than 15 years.
Risk factors
Genetic and environmental factors Treatment Chemotherapy, surgical resection of the tumor and radiation therapy.
Prognosis
Prognosis depends on the subtype. Prognosis is worse in the alveolar subtype than in the embryonal subtype. Finding in imaging Heterogeneous mass on CT.
MRI shows low signal in T1; high signal in T2 and heterogeneous T1 enhancement. 
